Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? – A systematic review

Trials

Lucas M Bachmann¹  Annalisa Perna³  Johann Steurer²  Milo A Puhan²  Madlaina Scharplatz² 

[1]Division of Epidemiology and Biostatistics, Department of Social and Preventive Medicine, University of Bern, Switzerland

[2]Horten Centre for patient oriented research, University of Zurich, Switzerland

[3]Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, "Aldo e Cele Daccò" Villa Camozzi, Bergamo, Italy

关键词: ACE I/D polymorphism;    pharmacogenetics;    Angiotensin-converting enzyme;   

Others  :  1107183
DOI  :  10.1186/1468-6708-6-16

 received in 2005-08-31, accepted in 2005-10-24,  发布年份 2005

【 摘 要 】

Background

Pharmacogenetic testing to individualize ACE inhibitor therapy remains controversial. We conducted a systematic review to assess the effect modification of the insertion/deletion (I/D) polymorphism of the ACE gene on any outcome in patients treated with ACE inhibitors for cardiovascular and/or renal disease.

Methods

Our systematic review involved searching six electronic databases, then contacting the investigators (and pharmaceutical industry representatives) responsible for the creation of these databases. Two reviewers independently selected relevant randomized, placebo-controlled trials and abstracted from each study details on characteristics and quality.

Results

Eleven studies met our inclusion criteria. Despite repeated efforts to contact authors, only four of the eleven studies provided sufficient data to quantify the effect modification by genotypes. We observed a trend towards better response to ACE inhibitors in Caucasian DD carriers compared to II carriers, in terms of blood pressure, proteinuria, glomerular filtration rate, ACE activity and progression to end-stage renal failure. Pooling of the results was inappropriate, due to heterogeneity in ethnicity, clinical domains and outcomes.

Conclusion

Lack of sufficient genetic data from the reviewed studies precluded drawing any convincing conclusions. Better reporting of genetic data are needed to confirm our preliminary observations concerning better response to ACE inhibitors among Caucasian DD carriers as compared to II carriers.

【 授权许可】

   
2005 Scharplatz et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM: National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2004, 110:724-731.
• [2]Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, Porcellati C: Meta-Analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. Am J Cardiol 2004, 93:240-243.
• [3]A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group J Am Coll Cardiol 1983, 2:755-763.
• [4]Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group N Engl J Med 1987, 316:1429-1435.
• [5]Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators N Engl J Med 1991, 325:293-302.
• [6]Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450-1456.
• [7]Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de ZD, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
• [8]Navis G, Van Der Kleij FGH, de Zeeuw D, de Jong PE: Angiotensin-converting enzyme gene I/D polymorphism and renal disease. J Mol Med 1999, 77:781-791.
• [9]Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998, 352:1252-1256.
• [10]Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC: Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004, 329:828.
• [11]Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group Lancet 1997, 349:1787-1792.
• [12]Suwelack B, Kempkes-Koch M, Kobelt V, Hillebrand U, Matzkies F, Gerhardt U, Hohage H: Impact of ACE polymorphism on renal allograft function, blood pressure, and proteinuria under ACE inhibition. Transplant Proc 2002, 34:1763-1766.
• [13]Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH, Hohage H: Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 2003, 16:313-320.
• [14]Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, Wallner M, Auinger M, Arias I, Schneider B, Mayer G: Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease 156. Kidney blood press res 1998, 21:66-69.
• [15]O'Toole L, Stewart M, Padfield P, Channer K: Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998, 32:988-994.
• [16]Opie LH, Przybojewski JZ: Angiotensin-converting enzyme inhibitor therapy. S Afr Med J 1992, 81:183-185.
• [17]Rigat B, Hubert C, Alhencgelas F, Cambien F, Corvol P, Soubrier F: An Insertion Deletion Polymorphism in the Angiotensin I-Converting Enzyme Gene Accounting for Half the Variance of Serum Enzyme Levels. J Clin Invest 1990, 86:1343-1346.
• [18]Mayer G: ACE genotype and ACE inhibitor response in kidney disease: a perspective. Am J Kidney Dis 2002, 40:227-235.
• [19]Scharplatz M, Puhan MA, Steurer J, Bachmann LM: What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review. BMC Med Genet 2004, 5:23. BioMed Central Full Text
• [20]ter-Riet G, Kessels AGH: Commentary on Rampes et al 'Does electroacupuncture reduce craving for alcohol? A randomized controlled study'. Complement Ther Med 1997, 116-118.
• [21]Okamura A, Ohishi M, Rakugi H, Katsuya T, Yanagitani Y, Takiuchi S, Taniyama Y, Moriguchi K, Ito H, Higashino Y, Fujii K, Higaki J, Ogihara T: Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology 1999, 50:811-822.
• [22]van Geel PP, Buikema H, Rouleau JL, van Gilst WH: Genotype-dependent increase in plasma ACE activity after CABG is prevented by ACE inhibition. Can J Cardiol 2003, 19:701-704.
• [23]Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong LA, Fuller JH: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998, 47:1507-1511.
• [24]Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000, 57:274-281.
• [25]Hernandez D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V, Higueras L, Martin B, Rodriguez A, Laynez I, Gonzalez-Posada JM, Torres A: Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000, 58:889-897.
• [26]Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown M: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995, 13:1602-1609.
• [27]Kvetny J, Gregersen G, Pedersen RS: Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. QJM 2001, 94:89-94.
• [28]Meurice T, Bauters C, Hermant X, Codron V, VanBelle E, Mc-Fadden EP, Lablanche J, Bertrand ME, Amouyel P: Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet 2001, 357:1321-1324.
• [29]Okumura K, Sone T, Kondo J, Tsuboi H, Mukawa H, Tsuzuki M, Imai H, Kamiya H, Mabuchi Y, Matsui H, Hayakawa T: Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele. Circ J 2002, 66:311-316.
• [30]Pedersen OD, Gram J, Jeunemaitre X, Billaud E, Jespersen J: Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. Coron Artery Dis 1997, 8:283-291.
• [31]Pinto YM, van Gilst WH, Kingma JH, Schunkert H: Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol 1995, 25:1622-1626.
• [32]Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Lancet 1997, 349:1857-1863.
• [33]Oosterga M, Voors AA, Buikema H, Pinto YM, Haber HE, Ebels T, Morshuis WJ, Kingma JH, Crijns HJ, van Gilst WH: Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators. Cardiovasc Drugs Ther 2000, 14:55-60.
• [34]Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998, 352:1252-1256.
• [35]Altman DG: Randomisation. BMJ 1991, 302:1481-1482.
• [36]Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273:408-412.
• [37]Colhoun HM, McKeigue PM, Davey SG: Problems of reporting genetic associations with complex outcomes. Lancet 2003, 361:865-872.
• [38]Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, Vlietinck R, Fagard R: The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997, 15:1579-1592.
• [39]Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de BA: Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics 2004, 14:53-60.